1. Specifications and validation of the ACMG/AMP criteria for clinical interpretation of sequence variants in collagen genes associated with joint hypermobility
- Author
-
Leone, Maria Pia, Morlino, Silvia, Nardella, Grazia, Pracella, Riccardo, Giachino, Daniela, Celli, Luca, Baldo, Demetrio, Turolla, Licia, Piccione, Maria, Salzano, Emanuela, Busè, Martina, Lastella, Patrizia, Zollino, Marcella, Cantone, Rachele, Grosso, Enrico, Zonta, Andrea, Pasini, Barbara, Piscopo, Carmelo, De Maggio, Ilaria, Priolo, Manuela, Mammi, Corrado, Foiadelli, Thomas, Trabatti, Chiara, Savasta, Salvatore, Iolascon, Achille, Ferraris, Alessandro, Lodato, Valentina, Di Giosaffatte, Niccolò, Majore, Silvia, Selicorni, Angelo, Petracca, Antonio, Fusco, Carmela, Celli, Mauro, Guarnieri, Vito, Micale, Lucia, Castori, Marco, Leone M.P., Morlino S., Nardella G., Pracella R., Giachino D., Celli L., Baldo D., Turolla L., Piccione M., Salzano E., Busè M., Lastella P., Zollino M., Cantone R., Grosso E., Zonta A., Pasini B., Piscopo C., De Maggio I., Priolo M., Mammi C., Foiadelli T., Trabatti C., Savasta S., Iolascon A., Ferraris A., Lodato V., Di Giosaffatte N., Majore S., Selicorni A., Petracca A., Fusco C., Celli M., Guarnieri V., Micale L., and Castori M.
- Subjects
ACMG/AMP criteria, variants in collagen genes, joint hypermobility ,Genetics ,ACMG/AMP criteria ,collagen genes ,hereditary connective tissue disorders (HCTD) ,Settore MED/03 - GENETICA MEDICA ,hereditary connective tissue disorders (HCTD), ACMG/AMP criteria, collagen genes ,Genetics (clinical) - Abstract
Deleterious variants in collagen genes are the most common cause of hereditary connective tissue disorders (HCTD). Adaptations of the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) criteria are still lacking. A multidisciplinary team was set up for developing specifications of the ACMG/AMP criteria for COL1A1, COL1A2, COL2A1, COL3A1, COL5A1, COL5A2, COL11A1, COL11A2 and COL12A1, associated with various forms of HCTD featuring joint hypermobility, which is becoming one of the most common reasons of referral for molecular testing in this field. Such specifications were validated against 209 variants, and resulted effective for classifying as pathogenic and likely pathogenic null alleles without downgrading of the PVS1 level of strength and recurrent Glycine substitutions. Adaptations of selected criteria reduced uncertainties on private Glycine substitutions, intronic variants predicted to affect the splicing, and null alleles with a downgraded PVS1 level of strength. Segregation and multigene panel sequencing data mitigated uncertainties on non-Glycine substitutions by the attribution of one or more benignity criteria. These specifications may improve the clinical utility of molecular testing in HCTD by reducing the number of variants with neutral/conflicting interpretations. Close interactions between laboratory and clinicians are crucial to estimate the a priori utility of molecular test and to improve medical reports.
- Published
- 2023
- Full Text
- View/download PDF